Sanofi's Rilzabrutinib Shows Promise in Phase 2 Trials for Chronic Spontaneous Urticaria

Sanofi-Aventis Groupe announced promising results from its Phase 2 RILECSU study, showcasing rilzabrutinib's ability to significantly reduce itch severity ...

February 26, 2024 | Monday | News
LimmaTech Biologics Announces Positive Interim Results for Shigella4V Vaccine in Phase I/II Trial

LimmaTech Biologics AG, announced encouraging interim results from its Phase I/II clinical trial evaluating Shigella4V (S4V), a promising tetravalent bioco...

February 22, 2024 | Thursday | News
Polpharma Biologics' Biosimilar Shows PK/PD Compatibility with Entyvio® for Inflammatory Bowel Disease

Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio® ...

February 21, 2024 | Wednesday | News
Aleta Biotherapeutics and Cancer Research UK Launch ALETA-001 Phase 1/2 Trial for Relapsed B-Cell Malignancies

Aleta Biotherapeutics (Aleta), a pioneer in immuno-oncology with a focus on CAR T-Cell Engager (CTE) platforms, in collaboration with Cancer Research UK&rs...

February 21, 2024 | Wednesday | News
Bayer AG and AskBio Initiate Phase II Trial of AB-1002 Gene Therapy for Congestive Heart Failure

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announ...

February 19, 2024 | Monday | News
Vidac Pharma's VDA-1275 Shows Promising Efficacy Across Solid Tumor Models and Enhances Standard Treatments

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a pioneering oncology biopharmaceutical company, has revealed prom...

February 19, 2024 | Monday | News
Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

  Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...

February 16, 2024 | Friday | News
FDA Grants Orphan-Drug Designation to Mesoblast's Revascor® for Congenital Heart Disease in Children

Mesoblast's Chief Executive, Silviu Itescu, expressed satisfaction with the FDA's decision: “We are very pleased to have now been granted both Orphan...

February 15, 2024 | Thursday | News
Corvus Pharmaceuticals Receives Orphan Drug Designation for Soquelitinib in T Cell Lymphoma, Advances Towards Phase 3 Clinical Trial

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a distinguished player in the clinical-stage biopharmaceutical arena, has achieved a significant milestone wit...

February 12, 2024 | Monday | News
Takeda Advances Global Phase 3 Trials of TAK-861 in Narcolepsy Type 1 Following Positive Phase 2b Results

Takeda  unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...

February 12, 2024 | Monday | News
Auron Therapeutics Unveils Groundbreaking Cancer Treatment Candidate AUTX-703 from AURIGIN™ Platform

    Auron Therapeutics, a pioneering biotechnology firm dedicated to advancing targeted cancer therapies, has announced the selection of its in...

February 08, 2024 | Thursday | News
Medidata and Sanofi Vaccines Forge Deeper Collaboration to Enhance Patient Centricity and Trial Efficiency

Medidata, a Dassault Systèmes company and a leading provider of clinical trial solutions to the life sciences industry, has joined forces with Sanof...

February 07, 2024 | Wednesday | News
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...

February 02, 2024 | Friday | News
Hummingbird Diagnostics Begins Patient Registration for miLungDx Trial, a Novel Early-Stage Lung Cancer Test

Hummingbird Diagnostics GmbH, a leader in the analysis of blood-based small RNA (sRNA) for the early detection and characterization of diseases, today anno...

January 24, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close